Renowned Scientist Christopher Mason, Ph.D. and Quantum-Si Collaborate for Exclusive GenomeWeb Webinar
27 Feb 2024
--(BUSINESS WIRE)--Quantum-Si Incorporated (NASDAQ: QSI):
'The Next 500 Years: Engineering Life to Reach New Worlds.'
WHAT: Esteemed scientist Christopher Mason, Ph.D., of Weill Cornell Medicine, is set to discuss his Two Frontiers Project during an exclusive webinar hosted by GenomeWeb. Dr. Mason will also reveal his plans for using Quantum-Si’s benchtop protein sequencer, Platinum® to expand his multiomic research on extremophiles and what is needed for human survival in extreme environments.
WHY: Dr. Mason recently remarked, “To better understand disease and health, we must not only look at nucleic acids, but also other molecules and pivotal proteins. In recent years, the field of proteomics has surged forward. We are now experiencing a remarkable acceleration with advancements in protein sequencing, revealing new biology and post-translational modifications.”
WHO: The webinar will feature:
Christopher Mason, Ph.D., Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine
Kenneth Skinner, Ph.D., Staff Scientist, Quantum-Si
WHEN: The webinar, titled “Characterizing Far-Flung Extremophiles with Next-Generation Protein Sequencing™,” will take place on Wednesday, February 28, at 11:00 a.m. ET.
WHERE: Hosted online by GenomeWeb. Reserve your spot today: https://event.on24.com/wcc/r/4461798/062AF09F1284EB44601D82D2A32B9869?partnerref=QSI
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
About Christopher Mason, Ph.D.
Christopher Mason, Ph.D., is a Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the director of the WorldQuant Initiative for Quantitative Prediction. With over 300 peer-reviewed papers, five patents, and the foundation of numerous biotechnology companies and non-profits, Dr. Mason is a leading figure in genomics and predictive algorithms for medicine. He is also the author of “The Next 500 Years: Engineering Life to Reach New Worlds.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.